Aytu BioPharma, Inc. (AYTU) |
| 2.025 -0.025 (-1.22%) 10-09 16:00 |
| Open: | 2.025 |
| High: | 2.025 |
| Low: | 2.02 |
| Volume: | 10,528 |
| Market Cap: | 22(M) |
| PE Ratio: | -1.71 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.39 |
| Resistance 1: | 2.20 |
| Pivot price: | 2.14 |
| Support 1: | 1.89 |
| Support 2: | 1.57 |
| 52w High: | 3.07 |
| 52w Low: | 1.8 |
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
| EPS | -1.160 |
| Book Value | 3.290 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.387 |
| Profit Margin (%) | -24.76 |
| Operating Margin (%) | -4.82 |
| Return on Assets (ttm) | -4.5 |
| Return on Equity (ttm) | -52.5 |
Wed, 07 Oct 2026
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy? - The Globe and Mail
Wed, 07 Oct 2026
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy? - Yahoo Finance
Wed, 30 Sep 2026
Aytu BioPharma (NasdaqCM:AYTU) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 29 Sep 2026
Aytu BioPharma at lytham partners fall 2026: exxua drives shift - Investing.com
Tue, 22 Sep 2026
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ... - Yahoo Finance
Tue, 22 Sep 2026
Aytu BioPharma reports FY2026 revenue $57.6M, Q4 revenue $16.1M and Adjusted EBITDA $0.5M - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |